Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8ZTPF)

Drug Name
(S)-Norfluoxetine Drug Info
Synonyms
126924-38-7; SEPROXETINE; UNII-25CO3X0R31; (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE; CHEMBL465123; (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; 25CO3X0R31; (S)-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Seproxetine [INN]; S-Norfluoxetine; AC1MHW5Z; SCHEMBL272873; ZINC4531; CTK8E9555; MolPort-005-941-621; 9173AH; BDBM50254790; AKOS027384574; DB06731; AJ-08214; RT-014029; FT-0673089; NFL_296.1257_14.5; J-005451
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3058751
CAS Number
CAS 126924-38-7
TTD Drug ID
DM8ZTPF
VARIDT Drug ID
DR00906

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Norepinephrine transporter (NET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [3]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [4]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [5]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [3]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [6]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [7]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [8]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [7]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [9]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [3]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [4]
Fluoxetine DM3PD2C Bipolar depression Approved [11]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [12]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [13]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [6]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [7]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [11]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [11]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [6]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [14]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [15]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [11]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [16]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [17]
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Attention deficit hyperactivity disorder 6A05.Z Approved [18]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [19]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [20]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Runt-related transcription factor 2 (RUNX2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [21]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [22]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [24]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [25]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [26]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [27]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [28]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [29]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Osteopontin (SPP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [21]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [31]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [32]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [33]
Quercetin DM3NC4M Obesity 5B81 Approved [34]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [35]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [25]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [36]
Panobinostat DM58WKG Chronic graft versus host disease Approved [37]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By SPARC (SPARC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [41]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [42]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [43]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [44]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [42]
Ethanol DMDRQZU Chronic pain MG30 Approved [45]
Folic Acid DMEMBJC Colorectal carcinoma Approved [46]
Paclitaxel DMLB81S Breast carcinoma Approved [47]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [1]
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [1]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Drug Response [2]
Runt-related transcription factor 2 (RUNX2) OT97RQQM RUNX2_HUMAN Drug Response [2]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Drug Response [2]

References

1 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
2 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
3 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
4 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
5 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
6 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
7 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
9 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
10 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
13 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
14 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
15 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
16 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
18 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
19 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
21 Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
22 Naringin protects human adipose-derived mesenchymal stem cells against hydrogen peroxide-induced inhibition of osteogenic differentiation. Chem Biol Interact. 2015 Dec 5;242:255-61. doi: 10.1016/j.cbi.2015.10.010. Epub 2015 Oct 19.
23 The role of simvastatin in the osteogenesis of injectable tissue-engineered bone based on human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2010 Jul;31(20):5325-35. doi: 10.1016/j.biomaterials.2010.03.037. Epub 2010 Apr 9.
24 Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem Pharmacol. 2006 Nov 15;72(10):1268-78. doi: 10.1016/j.bcp.2006.08.021. Epub 2006 Sep 22.
25 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
26 Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
27 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
28 How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett. 2012 Oct 17;214(2):145-53. doi: 10.1016/j.toxlet.2012.08.015. Epub 2012 Aug 30.
29 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
30 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
31 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
32 Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
33 Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
34 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
35 Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. J Atheroscler Thromb. 2000;7(2):77-82. doi: 10.5551/jat1994.7.77.
36 Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
37 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
38 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
39 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
40 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
41 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
42 Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
43 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
44 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
45 Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett. 2005 Jul 4;579(17):3651-9. doi: 10.1016/j.febslet.2005.05.056.
46 Folic acid modulates cancer-associated micro RNAs and inflammatory mediators in neoplastic and non-neoplastic colonic cells in a different way. Mol Nutr Food Res. 2017 Dec;61(12). doi: 10.1002/mnfr.201700260. Epub 2017 Nov 9.
47 Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.